CONCLUSION
ACD to suture material should be considered in patients who present with early and delayed post-procedural induration and erythema, particularly in the setting of repeated culture-negative episodes. This report highlights the potential for triclosan, and specifically triclosan-coated sutures, to contribute to ACD. A single interrupted stitch test into the dermis improves the sensitivity of in vivo testing for suture hypersensitivity when conventional patch allergen testing proves negative.  While this recognized entity remains an infrequent procedural complication, this is a treatable phenomenon which results in significant patient morbidity and increased costs to the healthcare system. Early consideration of ACD and engagement by a multi-disciplinary team including Infectious Disease and Allergy & Immunology leads to efficient diagnosis and improved patient outcomes.